Reprogramming of Human Melanocytes and Melanoma Cells with Yamanaka Factors

  • Hadiseh Taheri
  • Umut Cagin
  • Açelya YilmazerEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1916)


The expression of Yamanaka factors (Oct3/4, Klf-4, Sox-2, c-Myc) can reprogram cancer cells to a pluripotent stage. This may cause the removal of their epigenetic memory and result in altered tumorigenicity. Various studies in the literature have shown that cancer cell reprogramming is a potential tool to study disease progression or discover novel therapeutic or diagnostic markers in cancer research. In this chapter, we aim to introduce the cancer cell reprogramming protocol in detail by using human melanocytes and melanoma cell lines, and Sendai viral vectors encoding Yamanaka factors have been used to reprogram cells. Representative results are discussed and important notes have been summarized in order to point out important steps during cancer cell reprogramming.

Key words

Cell reprogramming iPS cells Yamanaka factors Cancer Disease modelling Therapy 


  1. 1.
  2. 2.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676CrossRefGoogle Scholar
  3. 3.
    Siller R, Greenhough S, Park IH, Sullivan GJ (2013) Modelling human disease with pluripotent stem cells. Curr Gene Ther 13(2):99–110CrossRefGoogle Scholar
  4. 4.
    Sng J, Lufkin T (2012) Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int 2012:521343. Scholar
  5. 5.
    Dawson Mark A, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27CrossRefGoogle Scholar
  6. 6.
    Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A, Bernstein BE, Meissner A (2011) Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell 8(1):96–105CrossRefGoogle Scholar
  7. 7.
    Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415. Scholar
  8. 8.
    Papp B, Plath K (2013) Epigenetics of reprogramming to induced pluripotency. Cell 152(6):1324–1343CrossRefGoogle Scholar
  9. 9.
    Yilmazer A, de Lázaro I, Taheri H (2015) Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling? Cancer Lett 369(1):1–8CrossRefGoogle Scholar
  10. 10.
    Yilmazer Aktuna A, Taheri H, Can A (2017) Efficient transduction of melanoma cells with Sendai viral vectors. Turk Hij Den Biyol Derg 74(2):113–120Google Scholar
  11. 11.
    Yilmazer A, Taheri H (2018) Reprogramming human melanocytes and melanoma cells with Yamanaka factors. Hacettepe J Biol Chem 46(1):35–41Google Scholar
  12. 12.
    Mochizuki H, Ohnuki Y, Kurosawa H (2011) Effect of glucose concentration during embryoid body (EB) formation from mouse embryonic stem cells on EB growth and cell differentiation. J Biosci Bioeng 111(1):92–97. Scholar
  13. 13.
    Okahara-Narita J, Umeda R, Nakamura S, Mori T, Noce T, Torii R (2012) Induction of pluripotent stem cells from fetal and adult cynomolgus monkey fibroblasts using four human transcription factors. Primates 53(2):205–213CrossRefGoogle Scholar
  14. 14.
    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Hadiseh Taheri
    • 1
    • 2
  • Umut Cagin
    • 3
  • Açelya Yilmazer
    • 1
    • 2
    • 4
    Email author
  1. 1.Biotechnology InstituteAnkara UniversityTandoganTurkey
  2. 2.Biomedical Engineering Department, Engineering FacultyAnkara UniversityGolbasiTurkey
  3. 3.Genethon, UMR_S951 Inserm, Univ Evry, Université Paris Saclay, EPHEEvryFrance
  4. 4.Stem Cell InstituteAnkara UniversityBalgatTurkey

Personalised recommendations